Azitra, Inc. Announces Positive Preclinical Data from ATR-04

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

ATR-04 is in development for epidermal growth factor receptor inhibitor -induced dermal toxicity, which affects approximately 150,000 patients in the US

Reduces methicillin-resistant S. aureus by...

Related Keywords

Dallas , Texas , United States , American , Travis Whitfill , Society Of Investigative Dermatology , Azitra Inc , Investigative Dermatology , Investigational New Drug , Private Securities Litigation Reform Act ,